Mirati Therapeutics Inc. has described GTPase KRAS (G12C mutant) inhibitors reported to be useful for the treatment of cancer, in particular non-small-cell lung cancer (NSCLC).
Sunovion Pharmaceuticals Inc. has divulged new trace amine-associated receptor 1 (TAAR1; TAR1) agonists and/or 5-HT2A and/or 5-HT7 receptor antagonists reported to be useful for the treatment of bipolar and autism spectrum disorders, schizophrenia, substance abuse and dependence, Alzheimer's, Parkinson's and metabolic diseases.
The University of Texas System and Massachusetts Institute of Technology (MIT) have synthesized transcription factor PU.1 inhibitors reported to be useful for the treatment of Alzheimer's disease.
The Cleveland Clinic Foundation has disclosed citron rho-interacting kinase (CRIK; CIT) inhibitors reported to be useful for the treatment of medulloblastoma and prostate cancer.
It’s taken eight years of jury trials, court reversals and appeals for Amgen Inc. to get the nod to argue its case before the U.S. Supreme Court on what is needed to meet the enablement standard for functional patent claims that envelop a genus.
Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. has described nonreceptor tyrosine-protein kinase TYK2 inhibitors reported to be useful for the treatment of psoriasis, asthma, type 1 diabetes, inflammatory bowel disease, gout, multiple sclerosis, rheumatoid arthritis and TNF receptor-associated periodic syndrome (TRAPS), among others.
Kallyope Inc. has synthesized glucose-dependent insulinotropic receptor (GDIR; GPR119) agonists reported to be useful for the treatment of metabolic and nutrition disorders.
Halia Therapeutics Inc. has disclosed serine/threonine-protein kinase Nek7 inhibitors reported to be useful for the treatment of cancer, asthma, obesity, type 2 diabetes, hepatitis, peritonitis, neurodegeneration and psoriasis, among others.
RSS